Therapeutic Area: Oncology

Immuno-genomic landscape of osteosarcoma

Wu et al.
Nature Communications
February 2020
immuneAccess
Authors and Affiliates
Wu CC1, Beird HC1, Andrew Livingston J2,3, Advani S3, Mitra A1, Cao S4, Reuben A5, Ingram D6, Wang WL6, Ju Z4, Hong Leung C7, Lin H7, Zheng Y1, Roszik J1, Wang W4, Patel S2, Benjamin RS2, Somaiah N2, Conley AP2, Mills GB8, Hwu P2, Gorlick R3, Lazar A6, Daw NC3, Lewis V9, Futreal PA10; 1 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3 Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5 Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 8 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9 Department of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 10 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. afutreal@mdanderson.org.

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas

Aslan et al.
Nature Communications
February 2020
Authors and Affiliates
Aslan K1,2,3,4, Turco V1,2, Blobner J1,2, Sonner JK1,2,5, Liuzzi AR6, Núñez NG6, De Feo D6, Kickingereder P7, Fischer M7, Green E1,2, Sadik A8, Friedrich M1,2, Sanghvi K1,2,3, Kilian M1,2,3, Cichon F1,2,3, Wolf L1,2, Jähne K1,2, von Landenberg A1,2, Bunse L1,2, Sahm F9,10, Schrimpf D9,10, Meyer J9,10, Alexander A1,3,7, Brugnara G7, Röth R11, Pfleiderer K1,7, Niesler B11, von Deimling A9,10, Opitz C8, Breckwoldt MO1,7, Heiland S7, Bendszus M7, Wick W12,13,14, Becher B6, Platten M15,16,17; 1 DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 2 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany. 3 Faculty of Biosciences, Heidelberg University, Heidelberg, Germany. 4 Immatics Biotechnologies GmbH, Tübingen, Germany. 5 Institute of Neuroimmunology and Multiple Sclerosis, Center for Molecular Neurobiology Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 6 Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland. 7 Department of Neuroradiology, Heidelberg University Medical Center, Heidelberg, Germany. 8 Brain Cancer Metabolism Group, German Cancer Research Center (DKFZ), Heidelberg, Germany. 9 DKTK Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany. 10 Department of Neuropathology, Heidelberg University Medical Center, Heidelberg, Germany. 11 nCounter Core Facility, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany. 12 Department of Neurology, Heidelberg University Medical Center, Heidelberg, Germany. 13 National Center for Tumor Diseases Heidelberg, DKTK, Heidelberg, Germany. 14 DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany. 15 DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 16 Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany. m.platten@dkfz-heidelberg.de. 17 Helmholtz Institute for Tranlational Oncology (HI-TRON), Mainz, Germany. m.platten@dkfz-heidelberg.de.

T Cell Repertoire in Combination with T cell Density Predicts Clinical Outcomes in Patients with Merkel Cell Carcinoma

Farah et al.
Journal of Investigative Dermatology
February 2020
immuneAccess
Authors and Affiliates
Maya Farah1,*, Alexandre Reuben2,*, Ivelina Spassova3, Richard K. Yang1, Linda Kubat3, Priyadharsini Nagarajan1, Jing Ning4, Wen Li4, Phyu P. Aung1, Jonathan L. Curry1,5,6, Carlos A. Torres-Cabala1,5, Courtney W. Hudgens6, Selma Ugurel7, Dirk Schadendorf7, Curtis Gumbs8, Latasha D. Little8, Andrew Futreal8, Ignacio I. Wistuba6, Victor G. Prieto1,5, Linghua Wang8, Michael K. Wong9, Jennifer A. Wargo8,10, Jürgen C. Becker3,7,11,, and Michael T. Tetzlaff1,6,; The University of Texas MD Anderson Cancer Center 1 Department of Pathology and Laboratory Medicine 2 Department of Thoracic/Head & Neck Medical Oncology 3Translational Skin Cancer Research, University Clinic Essen, Germany 4 Department of Biostatistics 5 Department of Dermatology 6 Department of Translational and Molecular Pathology 7 Department of Dermatology, University Clinic Essen, Germany 8 Department of Genomic Medicine 9 Department of Melanoma Medical Oncology 10Department of Surgical Oncology 11German Cancer Consortium (DKTK), German Cancer Center (DKFZ), Heidelberg, Germany

Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R- Dependent STING Activation by Tumor-Derived cGAMP

Zhou et al.
Immunity
February 2020
Authors and Affiliates
Yi Zhou,1,3 Mingjian Fei,1,3 Gu Zhang,1 Wei-Ching Liang,1 WeiYu Lin,1 Yan Wu,1 Robert Piskol,1 John Ridgway,1 Erin McNamara,1 Haochu Huang,1 Juan Zhang,1 Jaehak Oh,1 Jaina M. Patel,2 Diana Jakubiak,1 Jeff Lau,1 Beth Blackwood,1 Daniel D. Bravo,1 Yongchang Shi,1 Jianyong Wang,1 Hong-Ming Hu,2 Wyne P. Lee,1 Rajiv Jesudason,1 Dewakar Sangaraju,1 Zora Modrusan,1 Keith R. Anderson,1 Søren Warming,1 Merone Roose-Girma,1 and Minhong Yan1,4,* 1Genentech Inc., South San Francisco, CA, USA 2Cancer Immunobiology Laboratory, Earle A. Chiles Research Institute, Portland, OR, USA 3These authors contributed equally 4Lead Contact *Correspondence: minhong@gene.com

T-cell lymphoma secondary to checkpoint inhibitor therapy

Anand et al.
Journal for ImmunoTherapy of Cancer
February 2020
Authors and Affiliates
Anand K1, Ensor J2, Pingali SR3, Hwu P4,5, Duvic M4, Chiang S3, Miranda R4, Zu Y3, Iyer S6; 1 Houston Methodist Cancer Center, Houston, Texas, USA kartikanand88@gmail.com spiyer@mdanderson.org. 2 Houston Methodist Research Institute, Houston, Texas, USA. 3 Houston Methodist Cancer Center, Houston, Texas, USA. 4 University of Texas MD Anderson Cancer Center, Houston, Texas, USA. 5 Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6 University of Texas MD Anderson Cancer Center, Houston, Texas, USA kartikanand88@gmail.com spiyer@mdanderson.org.

Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy

Valpione et al.
Nature Cancer
February 2020
immuneAccess
Authors and Affiliates
Valpione S1,2, Galvani E1, Tweedy J1, Mundra PA1, Banyard A3, Middlehurst P4, Barry J3, Mills S4, Salih Z2, Weightman J5, Gupta A2, Gremel G1, Baenke F1, Dhomen N1, Lorigan PC2, Marais R1; 1 Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom. 2 The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, United Kingdom. 3 Advanced Imaging and Flow Cytometry, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom. 4 Manchester Cancer Research Centre Biobank, The Christie NHS Foundation Trust, 550 Wilmslow Road, Manchester M20 4BX, United Kingdom. 5 Molecular Biology Core Facility, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park SK10 4TG, United Kingdom.

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Sharma et al.
Nature Communications
January 2020
Authors and Affiliates
Sharma M1, Khong H1, Fa'ak F1, Bentebibel SE1, Janssen LME1, Chesson BC1, Creasy CA1, Forget MA1, Kahn LMS1, Pazdrak B1, Karki B1, Hailemichael Y1, Singh M1, Vianden C1, Vennam S2, Bharadwaj U3, Tweardy DJ3, Haymaker C1, Bernatchez C1, Huang S4,5, Rajapakshe K4, Coarfa C4, Hurwitz ME6, Sznol M7, Hwu P1, Hoch U2, Addepalli M2, Charych DH2, Zalevsky J2, Diab A1, Overwijk WW8,9,10,11; 1 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2 Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. 3 Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA. 4 Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA. 5 Dan L. Duncan Cancer Center, Houston, TX, USA. 6 Yale Comprehensive Cancer Center, New Haven, CT, USA. 7 Yale University Cancer Center, Yale University, New Haven, CT, USA. 8 Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com. 9 Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. woverwijk@nektar.com. 10 The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA. woverwijk@nektar.com. 11 Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Reuben et al.
Nature Communications
January 2020
immuneAccess
Authors and Affiliates
Alexandre Reuben,#1,2 Jiexin Zhang,#3 Shin-Heng Chiou,#4 Rachel M. Gittelman,#5 Jun Li,6 Won-Chul Lee,6 Junya Fujimoto,7 Carmen Behrens,1,7 Xiaoke Liu,1 Feng Wang,6 Kelly Quek,1 Chunlin Wang,8 Farrah Kheradmand,9 Runzhe Chen,1 Chi-Wan Chow,7 Heather Lin,3 Chantale Bernatchez,10 Ali Jalali,11 Xin Hu,6 Chang-Jiun Wu,6 Agda Karina Eterovic,12 Edwin Roger Parra,7 Erik Yusko,5 Ryan Emerson,5 Sharon Benzeno,5 Marissa Vignali,5 Xifeng Wu,13 Yuanqing Ye,13 Latasha D. Little,6 Curtis Gumbs,6 Xizeng Mao,10 Xingzhi Song,6 Samantha Tippen,6 Rebecca L. Thornton,6 Tina Cascone,1 Alexandra Snyder,5 Jennifer A. Wargo,2,6 Roy Herbst,14 Stephen Swisher,15 Humam Kadara,7 Cesar Moran,16 Neda Kalhor,16 Jianhua Zhang,6 Paul Scheet,13 Ara A. Vaporciyan,15 Boris Sepesi,15 Don L. Gibbons,1 Harlan Robins,5,17 Patrick Hwu,10 John V. Heymach,1 Padmanee Sharma,18,19 James P. Allison,19 Veera Baladandayuthapani,20 Jack J. Lee,20 Mark M. Davis,corresponding author21 Ignacio I. Wistuba,corresponding author1,7 P. Andrew Futreal,corresponding author6 and Jianjun Zhangcorresponding author1,6; 1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 2Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 3Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 4Institute for Immunity, Transplantation, and Infection Operations, Howard Hughes Medical Institute, 450 Serra Mall, Stanford, CA 94305 USA 5Adaptive Biotechnologies, 1551 Eastlake Ave East, Seattle, WA 98102 USA 6Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 7Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 8iRepertoire, Inc., 800 Hudson Way, Suite 2304, Huntsville, AL 35806 USA 9Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 USA 10Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 11Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 12Department of Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 13Department of Epidemiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 14Department of Medical Oncology, 333 Cedar Street, Yale Cancer Center, New Haven, CT 06510 USA 15Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 16Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 17Computational Biology Program, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109 USA 18Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 19Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 20Department of Biostatistics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe, Houston, TX 77030 USA 21Department of Microbiology and Immunology, Howard Hughes Medical Institute, Stanford, 450 Serra Mall, Stanford, CA 94305 USA

Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence

Pruessmann et al.
Nature Cancer
January 2020
immuneAccess
Authors and Affiliates
Wiebke Pruessmann 1,8,10, Julie Rytlewski 2,10, James Wilmott 3,10, Martin C. Mihm Jr1, Grace H. Attrill3, Beatrice Dyring-Andersen1,9, Paul Fields 2, Qian Zhan1, Andrew J. Colebatch3,4, Peter M. Ferguson3,4, John F. Thompson 3,5, Klaus Kallenbach6, Erik Yusko2, Rachael A. Clark1, Harlan Robins2,7, Richard A. Scolyer 3,4,10 and Thomas S. Kupper 1,10*; 1Department of Dermatology and Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, USA. 2Adaptive Biotechnologies, Seattle, WA, USA. 3Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia. 4Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 5Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia. 6Department of Surgical Pathology, Zealand University Hospital, Roskilde, Denmark. 7Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 8Present address: Department of Dermatology, University of Luebeck, Luebeck, Germany. 9Present address: Novo Nordisk Foundation Centre for Protein Research, University of Copenhagen, Copenhagen, Denmark. 10These authors contributed equally: Wiebke Pruessmann, Julie Rytlewski, James Wilmott, Richard A. Scolyer, Thomas S. Kupper.

Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma

Perumal et al.
Clinical Cancer Research
January 2020
Authors and Affiliates
Perumal D1,2, Imai N1,2, Laganà A3,4, Finnigan J1,2,5, Melnekoff D3,4, Leshchenko VV1,2, Solovyov A5,6,7, Madduri D1,2, Chari A1,2, Cho HJ1,2, Dudley JT3,4, Brody JD1,2,5, Jagannath S1,2, Greenbaum B5,6,7, Gnjatic S2,5, Bhardwaj N1,2,5, Parekh S8,2. Author information 1 Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. 2 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 3 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. 4 Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, New York. 5 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 6 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York. 7 Center for Computational Immunology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York. 8 Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York. samir.parekh@mssm.edu.